# Evopoint Biosciences Inc. clinical trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Evopoint Biosciences Inc. as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Evopoint Biosciences Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/evopoint-biosciences-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 16, 2026 | NCT07823049 | Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy | Evopoint Biosciences Inc. | Phase 3 | Recruiting | Pancreatic Cancer | 226 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823049) |
| July 28, 2026 | NCT07730580 | Study of XNW5004 Tablets in Advanced Prostate Cancer | Evopoint Biosciences Inc. | Phase 2 | Not yet recruiting | Advanced Prostate Cancer | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730580) |
| July 28, 2026 | NCT07730515 | Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma | Evopoint Biosciences Inc. | Phase 1/2 | Recruiting | Non-hodgkin Lymphoma, Peripheral T-cell Lymphoma | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730515) |
| July 16, 2026 | NCT07707674 | Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer | Evopoint Biosciences Inc. | Phase 1 | Not yet recruiting | Metastatic Pancreatic Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707674) |
| April 22, 2026 | NCT07545603 | Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma | Evopoint Biosciences Inc. | Phase 2 | Recruiting | Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma, Grade 3, Follicular Lymphoma Grade 3A | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545603) |
| January 8, 2026 | NCT07327294 | A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor | Evopoint Biosciences Inc. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07327294) |
| May 23, 2025 | NCT06987500 | A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment | Evopoint Biosciences Inc. | Phase 1/2 | Recruiting | Tumor, Solid | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06987500) |
| January 29, 2025 | NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | Evopoint Biosciences Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799637) |
| January 15, 2025 | NCT06776952 | A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell... | Evopoint Biosciences Inc. | Phase 3 | Recruiting | Relapsed/Refractory Peripheral T Cell Lymphoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06776952) |
| November 25, 2024 | NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | Evopoint Biosciences Inc. | Phase 1/2 | Recruiting | Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | 307 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06702995) |
| November 25, 2024 | NCT06702605 | To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma | Evopoint Biosciences Inc. | Phase 2 | Not yet recruiting | Relapsed/Refractory Peripheral T Cell Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06702605) |
| August 16, 2024 | NCT06558513 | To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors | Evopoint Biosciences Inc. | Phase 1/2 | Completed | Advanced Tumor, Lymphoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06558513) |
| September 5, 2023 | NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments... | Evopoint Biosciences Inc. | Phase 1/2 | Terminated | Carcinoma, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Prostate Cancer, Small-cell Lung Cancer... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06022757) |
| January 24, 2022 | NCT05204563 | Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302... | Evopoint Biosciences Inc. | Phase 3 | Completed | Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05204563) |
| January 24, 2022 | NCT05204368 | Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With... | Evopoint Biosciences Inc. | Phase 3 | Unknown | Complicated Urinary Tract Infection Including Acute Pyelonephritis | 780 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05204368) |
| March 17, 2021 | NCT04802863 | Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects | Evopoint Biosciences Inc. | Phase 1 | Completed | Bacterial Infections | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04802863) |
| March 16, 2021 | NCT04801043 | To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females. | Evopoint Biosciences Inc. | Phase 1 | Completed | Bacterial Infections | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04801043) |
| March 8, 2021 | NCT04787562 | Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function | Evopoint Biosciences Inc. | Phase 1 | Completed | Bacterial Infections | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04787562) |
| July 22, 2020 | NCT04482569 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin | Evopoint Biosciences Inc. | Phase 1 | Completed | Bacterial Infections | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04482569) |
| August 1, 2019 | NCT04040907 | The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject | Evopoint Biosciences Inc. | Phase 1 | Completed | Gout | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04040907) |
| April 3, 2019 | NCT03901950 | Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors | Evopoint Biosciences Inc. | Phase 1 | Completed | Advanced Solid Tumors | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03901950) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 7 |
| Phase 1/2 | 7 |
| Phase 2 | 3 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 8 |
| Recruiting | 7 |
| Not yet recruiting | 4 |
| Unknown | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Bacterial Infections | 4 |
| Pancreatic Neoplasms | 3 |
| Lymphoma, T-Cell, Peripheral | 3 |
| Uterine Cervical Neoplasms | 2 |
| Ovarian Neoplasms | 1 |
| Neoplasms | 1 |
| Lymphoma, Follicular | 1 |
| Lymphoma | 1 |
| Gout | 1 |
| Carcinoma | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Carcinoma, Transitional Cell | 1 |
| Prostatic Neoplasms | 1 |
| Small Cell Lung Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Lymphoma, Non-Hodgkin | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Warehouses in the United States](https://specstream.ai/data/businesses/warehouses/united-states)
- [Aesthetic medicine clinics in the United States](https://specstream.ai/data/businesses/aesthetic-medicine-clinics/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [B2B signage companies in the United States](https://specstream.ai/data/businesses/b2b-signage-companies/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
- [Certification bodies in the United States](https://specstream.ai/data/businesses/certification-bodies/united-states)
